Evidence map›Paper›PMID 41808012›Full record

ArticleJournal of medicinal chemistry2026

Novel Triazoloquinoxaline-Based Tubulin Polymerization Inhibitor Induces Necroptosis and Significantly Inhibits Metastatic Melanoma Tumor Growth.

Christopher J Clark, Shelby N Waddell, Garrett E Tessmer, Carl B Womack, Yang Xie, Brittney D Williams, Meirola A Endraws, Cole T Huddleston, Keiluhn D Pulis, Joshua Thammathong and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Christopher J ClarkDepartment of Chemistry, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.
Shelby N WaddellDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.ORCID 0000-0002-6021-1032
Garrett E TessmerDepartment of Biology, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.
Carl B WomackDepartment of Biology, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.
Yang XieDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.ORCID 0000-0003-0656-5152
Brittney D WilliamsDepartment of Biology, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.
Meirola A EndrawsDepartment of Biology, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.
Cole T HuddlestonDepartment of Biology, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.
Keiluhn D PulisDepartment of Biology, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.
Joshua ThammathongDepartment of Chemistry, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.
Kamil TanasDepartment of Chemistry, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.
Beari A JangirDepartment of Chemistry, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.
Dejian MaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Kevin L BickerDepartment of Chemistry, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.ORCID 0000-0002-8638-971X
Yaohong WangDepartment of Anatomical Pathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, United States.
April M WeissmillerMolecular Biosciences Program, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.ORCID 0000-0003-4505-0530
Wei LiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.ORCID 0000-0002-9522-4474
Souvik BanerjeeDepartment of Chemistry, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.ORCID 0000-0002-7811-2577

Funding

Targeting the colchicine site in tubulin for advanced melanomaR01CA148706 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LI, WEI, MILLER, DUANE D · 2011 to 2025
$5.3M
Discovery of fused heterocyclic pyrazine based novel anti-mitotic agents for metastatic melanomaR16GM154786 · NIGMS · MIDDLE TENNESSEE STATE UNIVERSITY · PI Souvik Banerjee · 2024 to 2026
$516k
Acquisition of a Q-TOF Mass SpectrometerS10OD010678 · OD · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LI, WEI · 2012 to 2012
$325k
NCI NIH HHS R01 CA148706NIGMS NIH HHS R16 GM154786NIH HHS S10 OD010678
6 · The paper itself

Abstract

Metastatic melanoma is the deadliest form of skin cancer, being responsible for 80% of skin cancer deaths. Small molecule colchicine-binding site inhibitors have previously demonstrated preclinical therapeutic efficacy in treating metastatic and paclitaxel-resistant melanoma. We report here on the design, synthesis, and biological evaluation of thirty-five novel triazoloquinoxaline-based compounds with promising therapeutic potential. The most potent analog,

Indexed as

Antineoplastic AgentsMelanomaNecroptosisQuinoxalinesTriazolesTubulinTubulin ModulatorsAnimalsApoptosisCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMiceMice, Inbred C57BLStructure-Activity RelationshipAntineoplastic AgentsQuinoxalinesTriazolesTubulinTubulin Modulators

Identifiers

PMID41808012
PMCPMC13108338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.